β-Cell Failure or β-Cell Abuse?

Karel Erion1 and Barbara E. Corkey2*

1 Division of Endocrinology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States, 2 Evans Department of Medicine, Obesity Research Center, Boston University School of Medicine, Boston, MA, United States

This review is motivated by the need to question dogma that has not yielded significant improvements in outcomes of Type 2 Diabetes treatment: that insulin resistance is the driver of β-Cell failure and resulting hyperglycemia. We highlight the fact that hyperlipidemia, insulin resistance, and hyperinsulinemia all precede overt diabetes diagnosis and can each induce the other when tested experimentally. New research highlights the importance of high levels of circulating insulin as both a driver of weight gain and insulin resistance. Data from our lab and others document that several nutrients and environmental toxins can stimulate insulin secretion at non-stimulatory glucose in the absence of insulin resistance. This occurs either by direct action on the β-Cell or by shifting its sensitivity to known secretagogues. We raise the next logical question of whether β-Cell dysfunction in Type 2 Diabetes is due to impaired function, defined as failure, or if chronic overstimulation of the β-Cell that exceeds its capacity to synthesize and secrete insulin, defined as abuse, is the main abnormality in Type 2 Diabetes. These questions are important as they have direct implications for how to best prevent and treat Type 2 Diabetes.

Keywords: hyperinsulinemia, beta-cell, obesity, insulin resistance, type 2 diabetes

METABOLIC ABNORMALITIES PRECEDING TYPE 2 DIABETES (T2D)

A long prodrome precedes the diagnosis of T2D that includes elevated fasting insulin, obesity, insulin resistance (IR), and dyslipidemia. According to the American Diabetes Association, fasting glucose values of 5.5 mM or less are considered normal, values between 5.6 and 6.9 are considered pre-diabetic and values above 7.0 mM define T2D. These are arbitrary thresholds since fasting plasma glucose does not exhibit a bi- or tri-modal distribution that might be used to derive clear cut points for pre-diabetes or diabetes diagnosis (1). Like other components of the prodrome, glucose levels also increase prior to diagnosis.

However, elevations in blood glucose are a late manifestation of a disease that is preceded by other well-established indicators of diminishing metabolic health including obesity with accompanying lipid abnormalities or hyperlipidemia (HL), elevated fasting insulin or hyperinsulinemia (HI), and IR. IR is usually described as the proximal cause of T2D that occurs only when the β-cell can no longer compensate for the increasing demands of IR (β-cell decline). However, IR is also defined by elevated insulin levels! Interestingly, there is no established or proposed mechanism by which IR can stimulate secretion except via glucose, which does not change during the so-called “compensatory” stage of the disease (2). Furthermore, there is no evidence in
most cases that IR precedes or causes HI. There is also no
evidence that HI does not occur first and cause IR (3, 4). Knowledge of what comes first is essential to establish causality and hence optimize preventive treatment if HI is indeed the initiating cause of IR.

There are logical flaws in the dogma attributing T2D to IR and defining T2D as the moment β-cells cannot keep up with demand. Secretory systems do not possess an infinite capacity to synthesize and secrete hormones but rather have a finite capacity for work with a distinct maximum secretory potential. Stimulation of β-cells beyond maximum cellular secretory capacity constitutes abuse, whether through continuous excess carbohydrate or lipid exposure or environmental toxins (5–7). Determination of whether T2D results from β-cell failure or β-cell abuse is essential to inform appropriate therapeutic interventions. If failure, or inability to respond is the problem, then the solution is to add exogenous insulin or stimulate its secretion further in response to elevated glucose, as is current practice. If β-cell abuse, due to exceeding the maximum secretory capacity of a normally constituted β-cell is the problem, then the solution is to stop the abuse as early as possible by diminishing HI, particularly if the abuse ultimately leads to β-cell failure.

**THE EVIDENCE ON TRAJECTORIES OR SEQUENCE OF DEVELOPMENT OF METABOLIC ABNORMALITIES IN THE POPULATION**

Large longitudinal studies could inform the relationships among HL, IR, and HI, the three key metabolic biomarkers that precede overt T2D. However, available data sets do not appear to provide convincing support for a specific sequence of development. On the other hand, animal studies and some human studies do provide limited evidence that each metabolic abnormality can lead to the other two if sustained, thus underpinning the rationale for seeking such clarification. For example, HL induced by high fat feeding in animals, or lipid infusion in humans, increases insulin secretion and induces IR (8). In another study evaluating the trajectory of metabolic changes, a linear increase in fasting glucose started 3 years before diagnosis of diabetes, whereas insulin sensitivity (HOMA) decreased during the 5 years before and β-cell function increased 4 years before diagnosis (9). In another study, South Asians exhibited increased fasting insulin and 2-h stimulated insulin well before diagnosis and demonstrated increased β-cell function (HOMA2-β) 7 years before diagnosis (10). Preteen HI predicts weight gain and T2D (9). Interestingly, BMI in young Finns (11–14) was not associated with adult T2D but fasting insulin was (15): in assessing parameters that predict T2D, it was found that progressors had high fasting and 2-h insulin levels. These limited data predict that HI can be a cause of both obesity (16) and IR. However, the frequency of specific trajectories in defined populations is not known and further research is needed to document the sequence of appearance of these biomarkers in the progression to T2D in order to identify the appropriate focus for prevention.

The importance of distinguishing basal vs. glucose-stimulated insulin secretion (GSIS) is depicted in Figure 1 [redrawn from Ferrannini et al. (17) based on data from 188 subjects undergoing a 120 min, 75 g oral glucose tolerance test]. In this figure, basal HI begins to manifest in obese individuals and in subjects with impaired glucose tolerance (IGT) as a rising basal and an increasing percentage of total insulin secretion (in blue). The ratio of GSIS to basal (GSIS fold increase shown above bars in Figure 1) is lower in obesity and IGT and is markedly reduced in T2D, although basal HI is sustained. Decreased GSIS, in conjunction with increased HI, was shown by mathematical modeling of β-cell glucose responses to be the hallmark of T2D progression (17).

**THE PROINSULIN:INSULIN RATIO AS A MARKER FOR OVERSTIMULATION OF SECRETION FROM THE β-CELL**

Stimulation of the β-cell during progression toward T2D may even be underestimated, as current assays do not take into account circulating proinsulin. Proinsulin is the immature form of the hormone insulin that is packaged into secretory granules at the Golgi apparatus during granule biogenesis. Cleavage of C-peptide by prohormone convertase enzymes PCSK2 and PCSK3 within the granule results in mature insulin which can then be secreted into circulation upon fusion of the granule with the plasma membrane (18). Under normal conditions conversion of proinsulin to insulin occurs to such an extent that secretion of proinsulin is nominal (19). However, as patients progress toward overt T2D there is a steady increase in proinsulin secretion and the circulating proinsulin:insulin ratio (20–22). Two hypotheses have emerged to account for this phenomenon: (1) reduced activity of prohormone convertase enzymes, possibly due to a rise in pH within the insulin granules or (2) a prolonged
increase in the rate of secretion prevents adequate time with which to properly process proinsulin to insulin. It is known that conversion of proinsulin to insulin takes ∼3 h (23).

Several factors argue that the increased proinsulin secretion in T2D is due to abuse, or prolonged stimulation of secretion beyond the normal capacity of the β-cell. First, we have previously published that changes in the secreted proinsulin:insulin ratio can be achieved in cultured β-cells by chronic exposure to excess lipid (24). This indicates that direct action on the β-cell and not IR per se is responsible for the aberrant proinsulin secretion. Second, artificial elevation of glucose for a prolonged period increases the proinsulin:insulin ratio in the absence of any apparent defect of proinsulin processing (25). Lastly, induction of β-cell rest either pharmacologically or via bariatric surgery rapidly normalizes the secreted proinsulin:insulin ratio (26, 27). These results even lead to the possibility that β-cell failure may result from prolonged overstimulation, as the proinsulin:insulin ratio remains significantly elevated in T2D despite the inability to respond acutely to stimuli. Above 7.0 mM glucose, it is reasonable to state that β-cells are likely to be in a chronically stimulatory state. Additionally, β-cells exposed to excess nutrients in the form of glucose and fatty acids have a left-shifted dose response for glucose-stimulated insulin secretion, further increasing the drive of the β-cell to secrete insulin (7).

COULD DIABETES BE CAUSED BY INSULIN HYPERSECRETION?

This raises the inadequately explored possibility that diabetes could be caused by long-term β-cell overstimulation that ultimately exceeds the maximum capacity of the secretory pathway. Such a possibility is consistent with the 9-fold increase in fasting, unstimulated insulin levels reported in some obese diabetic subjects (28). In contrast, a 9-fold increase in GSIS is considered a robust response in a lean individual.

β-Cell hypersecretion of insulin in the absence of a stimulatory fuel increases fat stores (24). HI also can cause IR through insulin-induced receptor down-regulation both in the periphery (29) and in the brain where HI-induced insulin resistance may abrogate its normal role as a satiety signal (30, 31). In addition, insulin causes IR by inducing lipogenesis and increasing lipid metabolites that are known to diminish insulin sensitivity (32).

Thus, HI can precede IR as shown in studies that artificially increased insulin in the circulation in man and rodents to cause IR and weight gain (33–35). Interestingly, inhibition of insulin secretion under HI conditions may not cause hyperglycemia but rather may improve weight loss when combined with dieting in obese humans (36–38). Further support for an initiating role for HI is the ability to predict diabetes in subjects with high plasma insulin concentrations among Pima Indians (39).

Rodents overexpressing the human insulin gene, or treated with exogenous insulin develop IR secondary to HI (33). In contrast, lowering insulin levels with diazoxide increases insulin sensitivity in rodents and humans (36, 37, 40). Lowering insulin using a novel β-cell K_{ATP} channel opener, NN414, also proved beneficial in rodents and humans (41–46).

Data from our laboratory have demonstrated that cultured clonal β-cells exposed to excess nutrients for as little as 24–48 h exhibit increased lipid content, increased basal insulin secretion, decreased insulin content and diminished GSIS as illustrated in Figure 2. Interestingly, these in vitro changes provide a model of what might happen over time in vivo. Using this model, we demonstrated that bezafibrate, a pan-PPAR agonist that decreases cellular triglyceride content by stimulating fat oxidation (47), prevents elevated basal insulin secretion. Additionally, we have observed that replacing long-chain fat with medium-chain fatty acid, which is not effectively stored as triglyceride, did not cause hypersecretion (data not shown) unlike long chain fatty acids (7). These findings implicate excess lipid stores in the β-cell as complicit in the induction of HI.

We and others have also identified environmental agents that can stimulate insulin secretion at basal glucose levels. These include common food additives (5, 28) estrogenic compounds including bis-phenol A (48, 49), plant extracts (50, 51), and even viruses (32).

Studies are needed to determine whether IR is primary, or secondary to HI, in animal models and in pre-diabetic humans treated with inhibitors of insulin secretion or nutrient regimens that markedly decrease the daily insulin requirement. Analysis of available data with diazoxide, NN414, and somatostatin support the concept that inhibition of insulin secretion can improve metabolic health in some cases (41–46).

BARIATRIC SURGERY HAS LED TO AMAZING INSIGHTS INTO DIABETES

Recovery from β-cell hypersecretion of insulin and amelioration of T2D occurs most frequently following bariatric surgery, but also less frequently after weight loss or a very low carbohydrate diet, provided that sufficient secretory capacity has been retained by the β-cells. The majority of patients with T2D are rapidly “cured” following bariatric surgery. Normalization of circulating insulin and glucose levels occurs within a week of surgery without appreciable weight loss (16). In contrast, normalization of muscle insulin sensitivity requires at least 3 months, although it too is eventually achieved (53). The mechanisms explaining this normalization of HI and T2D are unknown. The relatively quick recovery of β-cell function again implicates hypersecretion as the main driver of β-cell dysfunction in T2D, as generation of new islet cells is known to be very slow in adult humans (53, 54). Unfortunately, this reset of metabolic parameters is transient in some patients. T2D recurs in a percentage of bariatric surgery patients after several years (55, 56), and more frequently in African Americans. T2D is characterized by HI and that is the abnormality that is reset most rapidly following surgery but is also the earliest to recur in patients in whom T2D returns (16).

The common features of effective treatments are diminished β-cell demand and markedly decreased HI prior to resolution of IR, decreased intake of simple carbohydrates, decreased calorie intake, and increased fat oxidation. It should be noted that
CURRENT DOGMA UNDERPINS TREATMENT: PROBLEMS WITH THE CURRENT THERAPEUTIC APPROACHES

T2D and its complications continuously worsen over the course of the disease. Initial single drug therapy is followed by additional drugs as the disease and its complications continue to worsen. The first therapeutic given to newly diagnosed patients with T2D or even pre-diabetes is metformin, which does not act on the β-cell, but rather has been reported to decrease both BMI and HI (58–60), relieving rather than exacerbating some of the stress on the β-cell. However, metformin is not a cure as the disease generally progresses and requires additional medication to control blood glucose.

Despite the fact that T2D involves many metabolic abnormalities, treatment is focused only on normalizing glucose and is based on the dogma that “IR is the cause of T2D.” This has inhibited investigation into the alternative possibilities that T2D is a consequence of HL or HI and that these metabolic abnormalities precede and cause both IR and hyperglycemia.

In contrast to current dogma, if HI is the cause of IR, then stimulating further insulin secretion to overcome resistance may adversely impact long-term function of the β-cell, assuming that secretory capacity is not unlimited. If HI is the cause of IR, then stimulating further insulin secretion may actually sustain and worsen IR. Furthermore, HI may cause or increase obesity that will in turn sustain HL, HI, and IR. Decades of failure to prevent or reverse the diabetes epidemic based on the “IR dogma” suggest that the time has come to challenge this dogma and investigate other possibilities.

OTHER POSSIBILITIES. COULD IR, OBESITY, AND DIABETES BE CAUSED BY ABERRANT LIPID SIGNALING OR ENVIRONMENTAL CHEMICALS?

This perspective has focused, up to now, on HI as a potential initiating defect. An alternative and equally compelling cause of T2D could be excessive lipid accumulation and signaling in metabolically sensitive tissues. There is an association with lipid abnormalities in both HI and IR but where this fits into the sequence of deterioration has not been established. Evidence has been obtained that excess lipid accumulation increases basal insulin secretion (Figure 2), and induces IR in muscle and in liver (61–63). It is well established that there is a strong link between lipid abnormalities, particularly in diabetes and cardiovascular disease but here too the cause and effect relationships are still uncertain.

Importantly, HL is associated with diminished insulin clearance by the liver, an important contributor to HI (64, 65) and

the decrease in HI following bariatric surgery is much greater than that induced by paired nutrient intake (57) implicating a mechanism other than altered nutrient intake.
may be a compensatory mechanism in response to excessive β-cell stimulation. In insulin resistant states both HI and decreased insulin degradation occur together.

Recovery from ectopic lipid mediated HI and IR has also been shown to occur post gastric surgery, following weight loss or in response to a ketogenic diet. Assessment of whether HI is primary or secondary to IR or HI may be determined in animal models and pre-diabetic humans using stimulators of PPARs. Review of published studies with fibrates show a correlation between triglyceride levels and HbA1c in diabetic patients and show that bezafibrate improves HbA1c in patients with diabetes (66–70).

An additional potentially major contributor to obesity, diabetes and/or β-cell stress that requires serious consideration and much more research is the role of environmental chemicals. Evidence exists for an association of some persistent-organic-pollutants (POPs) with T2D but not enough to establish causality (71). Similarly, there is suggestive evidence for a role of arsenic in T2D (72). In addition, there is a positive association between obesity in offspring and maternal smoking during pregnancy (73) although further studies are needed to assess the link to T2D, if any. Confirmation of a causal association between environmental toxins and metabolic dysfunction also will require determining the targets of such chemicals or the removal of such agents from the environment. The temporal relationship, if any, between environmental toxins and either HI, HL, or IR is not known but could provide important insight into the initiating and sequential metabolic abnormalities leading to T2D. Current advancements in analytical techniques may permit more widespread assessment of the relationship between blood levels of environmental toxins and metabolic dysfunction.

CONCLUSIONS: β-CELL FAILURE OR β-CELL ABUSE?

To answer this question, we must determine whether diabetes is a disease of limited glucose storage capacity or an adaptive response to excess lipid or a toxic environment. It seems unlikely that unlimited capacity to secrete insulin is required of a healthy β-cell. However, by the time the disease is manifested, diabetics may be diminished in their capacity to handle glucose and could benefit from β-cell rest by initiating a more rigorous effort to decrease simple carbohydrate intake before β-cell failure worsens. Luckily unlike certain amino acids and fatty acids, carbohydrates are not an essential component of any diet and can be readily produced endogenously by the liver. Finally, we do not know whether inhibiting HI in normoglycemic individuals could be beneficial or would have adverse effects on glucose homeostasis.

The recognition of our failure to prevent or reverse diabetes, despite concerted research investigations, suggests that it is imperative to rigorously assess alternatives to current dogma. Obesity/T2D may be the biggest epidemic in human history (74). To prevent T2D, a better understanding of the drivers of this epidemic is needed. There has been comprehensive attention to genes, lifestyle and behavior, and current attention on the impact of the intra-uterine environment, epigenetics and the microbiome. None of this has yet proved beneficial in treating or preventing T2D.

Metabolic disease is increasing, and is chronic, expensive and debilitating. If current therapy is contributing to the problem, correction is needed. There is no evidence that β-cell failure is due to defective performance of β-cells. It is equally plausible that excess stress and overwork exceed a capacity that would be perfectly functional if the stress were removed. The capacity to drastically improve β-cell function in Type 2 Diabetic patients soon after bariatric surgery best illustrates this point. If correct, the optimal early intervention might be removal of stress and inhibition of fasting HI. It is also possible that altered lipid metabolism is the cause of HI, IR, and decreased insulin clearance. In this case, decreasing ectopic lipid might be the solution. On the other hand, if induction of metabolic dysfunction by environmental toxins is responsible, the solution could be to identify and remove such toxins.

Stimulation of GSIS when the normal capacity to respond is lost, i.e., following diagnosis of disease may never be an appropriate intervention. Thus, incorrect interpretation of causation may increase stress, damage β-cells and speed the onset of permanent insulin insufficiency. Large-scale human studies are needed to unequivocally demonstrate the benefit, or lack thereof, of reduced HI in T2D prevention or treatment. It will be critical to determine whether certain populations may benefit more than others in response to a reduction in HI.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

REFERENCES

1. Vistisen D, Colagiuri S, Borch-Johnsen K, Collaboration D. Bimodal distribution of glucose is not universally useful for diagnosing diabetes. Diabetes Care (2009) 32:397–403. doi: 10.2337/dc08-0867
2. Polonsky KS, Given BD, Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest. (1988) 81:442–8. doi: 10.1172/JCI113339
3. Blackard WG, Guzelian PS, Small ME. Down regulation of insulin receptors in primary cultures of adult rat hepatocytes in monolayer. Endocrinology (1978) 103:548–53. doi: 10.1210/endo-103-2-548
4. Freychet P, Forgue E, Le Marchand Y, Laudat MH. [Decreased number of insulin receptors in obesity: studies in the obese hyperglycemic mouse (author’s trans)]. Ann D’endocrinol. (1976) 37:87–8.
5. Simmons AL, Schlezinger J, Corkey BE. What are we putting in our food that is making us fat? Food additives, contaminants, and other putative contributors to obesity. Curr Obs Rep. (2014) 3:273–85. doi: 10.1007/s13679-014-0094-p
6. Berdan CA, Erion KA, Burritt NE, Corkey BE, Deeney JT. Inhibition of monoacylglycerol lipase activity decreases glucose-stimulated insulin secretion in INS-1 (832/13) cells and rat islets. PLoS ONE (2016) 11:e0149008. doi: 10.1371/journal.pone.0149008
24. Erion KA, Burritt NE, Corkey BE, Deeney JT. Chronic exposure to excess nutrients left-shifts the concentration dependence of glucose-stimulated insulin secretion in pancreatic beta-cells. J Biol Chem. (2015) 290:16191–201. doi: 10.1074/jbc.M114.620351

25. Alarcon C, Lehman S, Schuppin GT, Rhodes CJ. Increased secretory demand rather than a defect in the prosin secretion mechanism causes hyperproinsulinemia in a glucose-infusion rat model of non-insulin-dependent diabetes mellitus. J Clin Invest. (1995) 95:1032–9. doi: 10.1172/JCI117748
stores and insulin secretion in human islets cultured at high (11 mM) glucose. J Clin Endocrinol Metab. (2004) 89:795–805. doi: 10.1210/jc.2003-031120
45. Zdravkovic M, Kruse M, Rost KL, Moss J, Kecskes A. The effects of NN414, a SUR1/Kir6.2 selective potassium channel opener in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes (2007) 40:405–6. doi: 10.1055/s-2007-973062
46. Zdravkovic M, Kruse M, Rost KL, Moss J, Kecskes A, Dyrberg T. The effects of NN414, a SUR1/Kir6.2 selective potassium channel opener, in healthy male subjects. J Clin Pharmacol. (2005) 45:763–72. doi: 10.1177/0091270050576947
47. Fruchart JC, Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (2006) 42:39–64. doi: 10.1358/dt.2006.42.1.963528
48. Alonso-Magdalena P, Quesada I, Nadal A. Endocrine disruptors in the etiology of type 2 diabetes mellitus. Nat Rev Endocrinol. (2011) 7:346–53. doi: 10.1038/nrendo.2011.56
49. Alonso-Magdalena P, Ropero AB, Soriano S, Garcia-Arevol M, Ripoll C, Fuentes E, et al. Bisphenol-A acts as a potent estrogen via non-classical estrogen triggered pathways. Mol Cell Endocrinol. (2012) 355:201–7. doi: 10.1016/j.mce.2011.12.012
50. Persaud SJ, Al-Majed H, Raman A, Jones PM. Gymnema sylvestre stimulates in vitro insulin release by increased membrane permeability. J Endocrinol. (1999) 163:207–12. doi: 10.1677/joe.0.1632007
51. Hoa NK, Norberg A, Sillard R, Van Phan D, Thuan ND, Dzung DT, et al. The possible mechanisms by which phanoside stimulates insulin secretion from rat islets. J Endocrinol. (2007) 192:389–94. doi: 10.1677/joe.1.06948
52. Szopa TM, Ward T, Dronfield DM, Portwood ND, Taylor KW. Coxsackie B4 viruses with the potential to damage beta cells of the islets are present in clinical isolates. Diabetologia (1990) 33:325–8. doi: 10.1007/BF00404634
53. Reed MA, Pories WJ, Chapman W, Pender J, Bowden R, Barakat H, et al. Roux-en-Y gastric bypass corrects hyperinsulinemia implications for the remission of type 2 diabetes. J Clin Endocrinol Metab. (2011) 96:2525–31. doi: 10.1210/jc.2011-0165
54. Teta M, Long SY, Wartschow LM, Rankin MM, Kushner JA. Very slow turnover of beta-cells in aged adult mice. Diabetes (2005) 54:2557–67. doi: 10.2337/diabetes.54.9.2557
55. Adams TD, Davidson LE, Litwin SE, Kim J, Kolotkin RL, Nanjee MN, et al. Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med. (2017) 377:1143–53. doi: 10.1056/NEJMoa1700459
56. Bogun G, Betzel B, Homan J, Aarts EO, Pluimber N, de Boer H, et al. Long-term effects of laparoscopic Roux-en-Y gastric bypass on diabetes mellitus, hypertension and dyslipidemia in morbidity obese patients. Obes Surg. (2014) 24:1835–42. doi: 10.1007/s11695-014-1310-2
57. Cummings DE, Arterburn DE, Westbrook EO, Kuzma JN, Stewart WD, Chan CP, et al. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial. Diabetologia (2016) 59:94–53. doi: 10.1007/s00125-016-3903-9
58. Kulkarni AS, Brutsaert EF, Anghel V, Zhang K, Bloomgarden N, Pollak M, et al. Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults. Aging Cell (2018) 17:e12723. doi: 10.1111/acel.12723
59. Rethnakaran R, Choi H, Ye C, Kramer CK, Zimman B. Two-year trial of intermittent insulin therapy vs metformin for the preservation of beta-cell function after initial short-term intensive insulin induction in early type 2 diabetes. Diabetes Obes Metab. (2018) 20:1339–407. doi: 10.1111/dom.13236
60. Patane G, Piro S, Rubazzo AM, Anello M, Vigneri R, Purrello F. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes (2000) 49:735–40. doi: 10.2337/diabetes.49.5.735
61. Boden G, Chen X, Iqbal N. Acute lowering of plasma fatty acids lowers basal insulin secretion in diabetic and nondiabetic subjects. Diabetes (1998) 47:1609–12. doi: 10.2337/diabetes.47.10.1609
62. Boden G, Chen X, Rosner J, Barton M. Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes (1995) 44:1239–42. doi: 10.2337/diab.44.10.1239
63. Boden G, Chen X, Ruiz J, White IV, Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest. (1993) 93:2438–46. doi: 10.1172/JCI117252
64. Ader M, Stefanoski D, Kim SP, Richey JM, Ionut V, Catalanò KJ, et al. Hepatic insulin clearance is the primary determinant of insulin sensitivity in the normal dog. Obesity (2014) 22:1238–45. doi: 10.1002/oby.20625
65. Hsu IR, Kim SP, Kabir M, Bergman RN. Metabolic syndrome, hyperinsulinemia, and cancer. Am J Clin Nutr. (2007) 86:867–71. doi: 10.1093/ajcn/86.8.8675
66. Flory JH, Ellenberg S, Szapory PO, Strom BL, Hennessy S. Antidiabetic action of bezafibrate in a large observational database. Diabetes Care (2009) 32:547–51. doi: 10.2337/dc08-1809
67. Tenenbaum A, Fisman EZ. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipid control and diabetes prevention? Cardiovasc Diabetol. (2012) 11:140. doi: 10.1186/1475-2840-11-140
68. Tenenbaum A, Fisman EZ. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol. (2012) 11:125. doi: 10.1186/1475-2840-11-125
69. Tenenbaum B, Behar S, Boyko V, Adler Y, Fisman EZ, Tanne D, et al. Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes. Atherosclerosis (2007) 194:265–71. doi: 10.1016/j.atherosclerosis.2006.08.005
70. Teramoto T, Shirai K, Daida H, Yamada N. Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study. Cardiovasc Diabetol. (2012) 11:29. doi: 10.1186/1475-2840-11-29
71. Taylor KW, Novak RF, Anderson HA, Birnbaum LS, Blystone C, Devito M, et al. Evaluation of the association between persistent organic pollutants (POPs) and diabetes in epidemiological studies: a national toxicology program workshop review. Environ Health Perspect. (2013) 121:774–83. doi: 10.1289/ehp.1205502
72. Kuo CC, Moon K, Thayer KA, Navas-Acien A. Environmental chemicals and type 2 diabetes: an updated systematic review of the epidemiologic evidence. Curr Diab Rep. (2013) 13:831–49. doi: 10.1007/s11892-013-0432-6
73. Behl M, Rao D, Aagard K, Davidson TL, Levin ED, Slotkin TA, et al. Evaluation of the association between maternal smoking, childhood obesity, and metabolic disorders: a national toxicology program workshop review. Environ Health Perspect. (2013) 121:774–83. doi: 10.1289/ehp.1205502
74. Zannett PN. Diabetes and its drivers: the largest epidemic in human history? Clin Diabetes Endocrinol. (2017) 3:1. doi: 10.1016/j.clindea.2016.06.005

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling Editor declared a past co-authorship with one of the authors (BC).